tbuckley/cabot-search huggingface dataset:
Case 2-2020: A 64-Year-Old Man with Fever and Respiratory Failure
Authors: Marwan M. Azar, Victorine V. Muse, Julian A. Villalba, Sarah E. Turbett
Journal: New England Journal of Medicine (2020)

A 64-year-old man was admitted to the hospital because of acute renal failure presumed to be due to rapidly progressive glomerulonephritis. Plasma exchange and treatment with glucocorticoids, cyclophosphamide, and rituximab were initiated. About 2 weeks later, fever, painful oral ulcers, dyspnea on exertion, productive cough, and respiratory distress developed. A diagnostic test was performed.
Prognostic Impact of Serum Cyfra 21-1 In Advanced Lung Adenocarcinoma
Authors: A. Ono, T. Takahashi, H. Akamatsu, T. Taira, T. Shukuya, H. Kenmotsu, T. Naito, H. Murakami, M. Endo, N. Yamamoto
Journal: Annals of Oncology (2012)
Discordance of the ER- and HER2-status on disseminated tumor cells (DTCs) compared to the primary tumor (PT) in patients with early breast cancer (BC).
Authors: Bernadette Anna Sophia Jaeger, Charlotte Finkenzeller, Carolin Bock, Leonie Majunke, Julia Kathrin Jueckstock, Ulrich Andergassen, Julia Katharina Neugebauer, Aurelia Pestka, Thomas W. P. Friedl, Udo Jeschke, Wolfgang Janni, Sophie F Doisneau-Sixou, Brigitte Kathrin Rack
Journal: Journal of Clinical Oncology (2013)

e22059 Background: The goal of this study was to evaluate both ER- and HER2-status on DTCs in the bone marrow of patients with early BC and to compare these with the corresponding PT. In case of discordant expression, DTCs might help in properly selecting targeted therapy according to their phenotype. Methods: Bone marrow (BM) samples were obtained from early BC patients at the time of first breast surgery (years 2006 to 2009). Two cytospins with 10 6 BM cells were prepared after Ficoll enrichment for mononuclear cells. We were able to determine the presence of DTCs (cytokeratin (CK) + cells) in a total of 58 patients. Simultaneously ER- and HER2-expressions were analyzed by immunocytochemistry using a triple fluorescence staining method. Briefly, antibodies (AB) directed against human ER (secondly labeled with Cy3, red), HER2 (DyLight488, blue) and CK (Coumarin-AMCA, green) were used. The manual analysis was conducted using a computerized fluorescence microscope (Axioskop, Zeiss, Germany). Criteria for CK-positivity and HER2-overexpression were the ring-like appearance of the respective membrane-staining and for ER-expression a nuclear staining. Data on ER- and HER2-status of the PT were available for all 58 and 54 of the patients respectively. Results: The median number of DTCs detected was 12 (range 1-95; total number of DTCs 1132). 41 (71%) of the patients had at least one ER + DTC, 25 (43%) at least one HER2 + DTC, 15 (26%) at least one ER + /HER2 + DTC and 13 (22%) had DTCs neither expressing ER nor HER2. The concordance rate between ER-status on DTCs and PT was 74%. 6 (43%) patients with ER - PT had ER + DTCs. The concordance rate between HER2-status on DTCs and PT was 52% and 22 (46%) patients with HER2 - PT had HER2 + DTCs. Seven out of 10 patients with a triple-negative PT had at least one DTC positive for ER, HER2, or both. Conclusions: Our study confirms that the ER- and/or HER2-status on DTCs might differ compared to the PT. This discordance, which we demonstrated at the protein level, could be especially important for patients with a triple-negative PT and ER + or HER2 + DTCs, since they might respond favorably to an endocrine or HER2-targeted therapy.
Preliminary Safety Data from Randomized Phase II Study Comparing Dose-Escalated Weekly Paclitaxel Versus Standard-Dose Weekly Paclitaxel for Patients with Previously Treated Advanced Gastric Cancer
Authors: M. Nakamura, K. Shitara, S. Yuki, D. Takahari, C. Kondo, T. Tsuda, T. Kii, Y. Tsuji, D. Ichikawa, S. Utsunomiya, A. Hosokawa, A. Ishiguro, I. Oze, K. Muro
Journal: Annals of Oncology (2012)
Factors predictive of receiving neoadjuvant versus adjuvant chemoradiotherapy in locally advanced rectal cancer and the impact on overall survival.
Authors: Alex Richard Coffman, Dustin Boothe, Jonathan Evans Frandsen, Molly Gross, Thomas Bartley Pickron, Courtney L. Scaife, Shane Lloyd
Journal: Journal of Clinical Oncology (2017)

686 Background: Neoadjuvant chemoradiotherapy (NCRT) is generally accepted as the optimal treatment strategy compared to adjuvant chemoradiotherapy (ACRT) for locally advanced rectal cancer due to improvement in local control and reduced toxicity. However, NCRT has not been shown to improve overall survival (OS). We investigated the effect of NCRT versus ACRT on OS as well as the impact of demographic factors and clinical stage for the selection of each treatment approach utilizing the National Cancer Data Base. Methods: Adult patients with stage II and stage III adenocarcinoma of the rectum diagnosed from 2004-2013 were included. Chi-square analysis was used to compare demographic variables and clinical stage between the NCRT and ACRT treatment groups. Univariate and multivariate logistic regression modeling was used to identify factors predictive of each treatment strategy. Kaplan Meier and log-rank analysis along with propensity score matching was performed to determine the effect on OS. Results: A total of 20,262 patients were identified: 17,737 (87.5%) received NCRT and 2,525 (12.5%) received ACRT. Utilization of NCRT increased over the study period (p &lt; 0.01). Factors associated with receipt of NCRT on multivariate analysis include: treatment at an academic institution (OR 0.76, 95% CI 0.68-0.85), income greater than $46,000 (OR 0.79, 95% CI 0.67-0.92), and living greater than 50 miles from a treatment facility. Factors associated with receipt of ACRT on multivariate analysis include: female sex (OR 1.12, 95% CI 1.01-1.24), Charlson comorbidity index of 1 (OR 1.18, 95% CI 1.04-1.34), and radiotherapy dose greater than 5040 centigray (OR 1.76, 95% CI 1.56-1.98). Compared to ACRT, NCRT was associated with a decreased risk of death on multivariate analysis (HR 0.91, 95% CI 0.84-1.00), which persisted after propensity score analysis. Conclusions: The use of NCRT for locally advanced rectal cancer is increasing and is associated with an OS benefit compared to ACRT.
Vagal sensory neurons drive mucous cell metaplasia
Authors: Sébastien Talbot, Benjamin Doyle, Junwei Huang, Jo-Chiao Wang, Maryam Ahmadi, David P. Roberson, Ajay Yekkirala, Simmie L. Foster, Liam E. Browne, Bruce P. Bean, Bruce D. Levy, Clifford J. Woolf
Journal: Journal of Allergy and Clinical Immunology (2020)
Neuropathic Pain: Mechanism-Based Therapeutics
Authors: Kirsty Bannister, Juliane Sachau, Ralf Baron, Anthony H. Dickenson
Journal: The Annual Review of Pharmacology and Toxicology (2020)

Neuropathic pain (NeP) can result from sources as varied as nerve compression, channelopathies, autoimmune disease, and incision. By identifying the neurobiological changes that underlie the pain state, it will be clinically possible to exploit mechanism-based therapeutics for maximum analgesic effect as diagnostic accuracy is optimized. Obtaining sufficient knowledge regarding the neuroadaptive alterations that occur in a particular NeP state will result in improved patient analgesia and a mechanism-based, as opposed to a disease-based, therapeutic approach to facilitate target identification. This will rely on comprehensive disease pathology insight; our knowledge is vastly improving due to continued forward and back translational preclinical and clinical research efforts. Here we discuss the clinical aspects of neuropathy and currently used drugs whose mechanisms of action are outlined alongside their clinical use. Finally, we consider sensory phenotypes, patient clusters, and predicting the efficacy of an analgesic for neuropathy.
Cabazitaxel in Patients with Advanced CRPC after Docetaxel-Failure. Results of Expanded Program Access (EAP) in Spain: Safety and Efficacy
Authors: D.E. Castellano, L.M. Anton Aparicio, E. Esteban, G. Velasco, Q. Perez, A. Sanchez, B. Pérez-Valderrama, N. Batista
Journal: Annals of Oncology (2012)
Efficacy and Toxicity Observed in Malignant Pleural Mesothelioma Patients Treated in Phase I Trials at a Single Institution
Authors: J. Raphael, A. Hollebecque, G. Le Teuff, C. Massard, R. Bahleda, J. Margery, B. Besse, J. Soria, D. Planchard
Journal: Annals of Oncology (2012)
Retrospective Study of Chemotherapy for Unresectable Stage IVB Pancreatic Cancer
Authors: H. Kawabata, N. Sakiyama, Y. Okada, K. Sanada, K. Nakase, K. Mandai, A. Suzuki, S. Morikawa, T. Kawamura, A. Morita, M. Miyata, K. Uno, K. Tanaka, K. Yasuda
Journal: Annals of Oncology (2012)
Retrospective Analysis of Treatment with Bevacizumab in Patients with Advanced and recurrent Non-Squamous Non-Small-Cell Lung Cancer in our Institute
Authors: R. Yoshino, Y. Tomizawa, Y. Miura, M. Nishioka, A. Yoshii, S. Watanabe, R. Saitou, M. Mori
Journal: Annals of Oncology (2012)
Updated Analysis: Phase II Trial of Combined Chemotherapy with Irinotecan, S-1, and Bevacizumab (IRIS/Bev) in Patients with Metastatic Colorectal Cancer: Hokkaido Gastrointestinal Cancer Study Group (HGCSG) Trial
Authors: S. Yuki, Y. Komatsu, H. Nakatsumi, Y. Kobayashi, S. Takeuchi, S. Sogabe, T. Miyagishima, T. Kato, K. Hatanaka, M. Nakamura, M. Kudo, N. Akakura, N. Sonoda, M. Munakata, Y. Sakata
Journal: Annals of Oncology (2012)
Novel Strategy for Designing and Optimizing of Dendritic – Cell – Based Anticancer Vaccine
Authors: N. Khranovska, G.P. Potebnia, O.V. Skachkova, O.A. Tanasienko, N.M. Svergun, V.V. Sitko, O.G. Fedorchuk, V.V. Niculina
Journal: Annals of Oncology (2012)
Hera Trial: 2 Years Versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with Her2-Positive Early Breast Cancer at 8 Years of Median Follow up
Authors: A. Goldhirsch, M. Piccart, M. Procter, E. De Azambuja, H. Weber, M. Untch, I.E. Smith, L. Gianni, C. Jackisch, D. Cameron, R. Bell, M. Dowsett, R.D. Gelber, B. Leyland-Jones, J. Baselga
Journal: Annals of Oncology (2012)
Publisher Correction: Therapies for rare diseases: therapeutic modalities, progress and challenges ahead
Authors: Erik Tambuyzer, Benjamin Vandendriessche, Christopher P. Austin, Philip J. Brooks, Kristina Larsson, Katherine I. Miller Needleman, James Valentine, Kay Davies, Stephen C. Groft, Robert Preti, Tudor I. Oprea, Marco Prunotto
Journal: Nature Reviews Drug Discovery (2020)
Phase IB Trial of Imo-2055 in Combination with 5-Fu, Cisplatin and Cetuximab in 1st-Line PTS with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (R/M SCCHN)
Authors: J.P. Machiels, M.C. Kaminsky, U. Keller, T.H. Brümmendorf, T. Goddemeier, U. Forssman, J.P. Delord
Journal: Annals of Oncology (2012)
Efficacy and Safety of Anti–PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
Authors: Florian Guisier, Catherine Dubos-Arvis, Florent Viñas, Helene Doubre, Charles Ricordel, Stanislas Ropert, Henri Janicot, Marie Bernardi, Pierre Fournel, Régine Lamy, Maurice Pérol, Jerome Dauba, Gilles Gonzales, Lionel Falchero, Chantal Decroisette, Pascal Assouline, Christos Chouaid, Olivier Bylicki
Journal: Journal of Thoracic Oncology (2020)

IntroductionImmune-checkpoint inhibitor (ICI) efficacy in patients with NSCLC harboring molecular alterations remains poorly elucidated. This study was undertaken to determine ICI efficacy against BRAF-, HER2-, MET-, and RET-NSCLC in a real-world setting.MethodsIn this retrospective, multicenter study in ICI-treated BRAF-, HER2-, MET- or RET-NSCLCs, we analyzed clinical characteristics and outcomes: ICI-treatment duration, progression-free survival (PFS), objective response rate, duration of response, and overall survival (OS).ResultsThere were 107 patients with NSCLC (mean age, 65.5 y) included from 21 centers: 37% were never-smokers, 54% were men, and 93% had adenocarcinoma. Among them, 44 had BRAF mutation (V600: 26), 23 had HER2 mutation, 30 had MET mutation, and nine had RET translocation. Programmed cell death ligand 1 (PD-L1) status was known for 70 patients and was greater than or equal to 1% in 34 patients. Before ICI, patients had received a median of one treatment line. Median duration of response, PFS, and OS were 15.4 (95% confidence interval [CI]: 12.6–not reached [NR]) months, 4.7 (95% CI: 2.3–7.4) months, and 16.2 (95% CI: 12.0–24.0) months, respectively, for the entire cohort. The response rates for BRAF-V600, BRAF–non-V600, HER2, MET, and RET-altered NSCLC were 26%, 35%, 27%, 36%, and 38%, respectively. For patients who were PD-L1 negative and those who were PD-L1 positive, PFS was 3.0 (95% CI: 1.2–NR) and 4.3 (95% CI: 2.1–8.5) months, respectively, and OS was 11.7 (95% CI: 4.1–NR) and 35.8 (95% CI: 9.0–35.2) months, respectively. Toxicities were reported in 28 patients (26%), including 11 patients (10%) with a grade greater than or equal to three.ConclusionsIn this real-world setting, ICI efficacy against patients with BRAF-, HER2-, MET-, or RET-NSCLC seemed close to that observed in unselected patients with NSCLC. Large prospective studies on these subsets of patients are needed.
Advantages of One Step Nucleic Acid Amplification (OSNA) Whole Node Assay in Sentinel Lymph Node (SLN) Analysis in Breast Cancer
Authors: A. Santaballa, H. La De Cueva, C. Salvador, A. Garcia Martinez, M.J. Guarin, D. Lorente, L. Palomar, I. Aznar, F. Dobon, P. Bello
Journal: Annals of Oncology (2012)
Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity
Authors: Rui Li, Yanping Li, Jinhang Zhang, Qinhui Liu, Tong Wu, Jian Zhou, Hui Huang, Qin Tang, Cuiyuan Huang, Ya Huang, Zijing Zhang, Guorong Zhang, Yingnan Zhao, Liang Ma, Yanhuan Feng, Li Mo, Min Han, Jinhan He
Journal: Journal of Controlled Release (2020)
Metronomic chemotherapy following the maximum tolerated dose as a multitarget antitumor therapy affecting angiogenesis, tumor dissemination, and cancer stem cells.
Authors: Marta Vives, Mireia M. Ginestà, Kristina Gracova, Mariona Graupera, Oriol Casanovas, Gabriel Capella, Teresa Serrano, Francesc Vinyals, Berta Laquente Saez
Journal: Journal of Clinical Oncology (2013)

e22057 Background: Metronomic chemotherapy has been suggested as a maintenance administration strategy after the Maximum Tolerated Dose (MTD) treatment in a multi-targeted chemo-switch schedule (C-S). We report the effectiveness of this chemo-switch schedule in mice models of human pancreatic and ovarian cancer. Methods: In pancreas cancer models, Gemcitabine (G) was administered on four different schedules: metronomic (METG), Maximum Tolerated Dose (MTDG), chemo-switch schedule (C-SG, MTDG dosing followed by the METG) and anti-angiogenic (MTDG followed by the administration of monoclonal anti-VEGF receptor antibody DC101). In ovarian cancer model, animals were treated following a Cyclophosphamide chemo-switch schedule (C-S CTX). Results: In all these models C-S schedule had the most favorable effect, reaching at least 80% of tumor growth inhibition in absence of increased toxicity. Moreover, in the pancreas cancer model while peritoneal metastases were observed in control and MTD groups, no dissemination was observed in the MET and C-S groups. C-S treatment caused a decrease in angiogenesis and its effect on tumor growth was similar to obtained by the MTD followed by anti-angiogenic DC101 treatment. At the molecular level, C-S treatment combined an increase in thrombospondin-1 expression with a decrease in number of CD133+ cancer cells and triple positive CD133+/CD44+/CD24+ cancer stem cells. Conclusions: These findings provide confirmation that the chemo-switch schedule is a challenging clinical strategy with demonstrated inhibitory effects on tumor dissemination, angiogenesis and cancer stem cells.
Statement in response to calls for banning evidence-based supportive health interventions for transgender and gender diverse youth
Authors: Scott Leibowitz, Jamison Green, Ren Massey, Alison Mohr Boleware, Diane Ehrensaft, Will Francis, Colt Keo-Meier, Aydin Olson-Kennedy, Seth Pardo, G. Nic Rider, Emmett Schelling, Andrea Segovia, Vin Tangpricha, Erica Anderson, Guy T’Sjoen
Journal: International Journal of Transgender Health (2020)

Diversity in gender expression and variations in gender identity represent normative developmental processes for children and adolescents and are not inherently pathological aspects of the human ex...
Lace-Bio Pooled Analysis of the Prognostic and Predictive Value of TP53 Mutations in Completely Resected Non Small Cell Lung Cancer (NSCLC)
Authors: P. Hainaut, X. Ma, B. Lacas, M. Tsao, J. Douillard, V. Rousseau, A. Dunant, L. Seymour, M. Filipits, S. Graziano
Journal: Annals of Oncology (2012)
Artemisinin‐derived antimalarial endoperoxides from bench‐side to bed‐side: Chronological advancements and future challenges
Authors: Mohit K. Tiwari, Sandeep Chaudhary
Journal: Medicinal Research Reviews (2020)

Abstract According to WHO World Malaria Report (2018), nearly 219 million new cases of malaria occurred and a total no. of 435 000 people died in 2017 due to this infectious disease. This is due to the rapid spread of parasite‐resistant strains. Artemisinin (ART), a sesquiterpene lactone endoperoxide isolated from traditional Chinese herb Artemisia annua , has been recognized as a novel class of antimalarial drugs. The 2015 “Nobel Prize in Physiology or Medicine” was given to Prof Dr Tu Youyou for the discovery of ART. Hence, ART is termed as “Nobel medicine.” The present review article accommodates insights from the chronological advancements and direct statistics witnessed during the past 48 years (1971‐2019) in the medicinal chemistry of ART‐derived antimalarial endoperoxides, and their clinical utility in malaria chemotherapy and drug discovery.
Concurrent Chemoradiation (CCHRT) with Bi-Weekly Docetaxel and Cisplatin and Thoracic Radiotherapy for Stage III Non-Small Cell Lung Cancer (NSCLC): A Phase II Study from the Galician Lung Cancer Group
Authors: J. Casal Rubio, B. Taboada, M. Lazaro, S. Vazquez, X.L. Firvida, M. Vieito Villar, E. Hernández, J.E. Castro, F. Barón, C. Pena
Journal: Annals of Oncology (2012)
Prognostic Significance of EGFR, HER-2, CEA on Circulatingtumour Cells (CTCS) in Patients with Metastatic Non-Small-Cell Lung Cancer (MNSCLC)
Authors: C. Loretelli, E. Galizia, M. Scartozzi, R. Giampieri, D. Gagliardini, C. Brugiati, S. Cascinu, R. Cellerino
Journal: Annals of Oncology (2012)
The Preclinical Pharmacological Profile of Anamorelin/Ono-7643, A New Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia
Authors: C. Pietra, Y. Takeda, N. Tazawa-Ogata, M. Minami, X. Yuanfeng, E. Duus, R. Northrup
Journal: Annals of Oncology (2012)
Health Care Hotspotting — A Randomized, Controlled Trial
Authors: Amy Finkelstein, Annetta Zhou, Sarah Taubman, Joseph Doyle
Journal: New England Journal of Medicine (2020)

There is widespread interest in programs aiming to reduce spending and improve health care quality among "superutilizers," patients with very high use of health care services. The "hotspotting" program created by the Camden Coalition of Healthcare Providers (hereafter, the Coalition) has received national attention as a promising superutilizer intervention and has been expanded to cities around the country. In the months after hospital discharge, a team of nurses, social workers, and community health workers visits enrolled patients to coordinate outpatient care and link them with social services.
A Phase II Study of SB939 in Patients (PTS) with Castration Resistant Prostate Cancer (CRPC)
Authors: B.J. Eigl, S. North, E. Winquist, J. Powers, J. Good, M. Sharma, J. Squire, M. Cox, E.A. Eisenhauer, K. Chi
Journal: Annals of Oncology (2012)
Clinic and Home Blood Pressure Measurements are Reliable for Guiding Therapy in Patients with Metastatic Renal Cell Carcinoma Receiving Axitinib as First-Line Therapy
Authors: V. Grünwald, M.N. Fishman, M. Carducci, A. Bair, Y. Chen, S. Kim, B.I. Rini
Journal: Annals of Oncology (2012)
Xpert MTB/RIF Ultra versus Xpert MTB/RIF for the diagnosis of tuberculous meningitis: a prospective, randomised, diagnostic accuracy study
Authors: Joseph Donovan, Do Dang Anh Thu, Nguyen Hoan Phu, Vu Thi Mong Dung, Tran Phu Quang, Ho Dang Trung Nghia, Pham Kieu Nguyet Oanh, Tran Bao Nhu, Nguyen Van Vinh Chau, Vu Thi Ngoc Ha, Vu Thi Ty Hang, Dong Huu Khanh Trinh, Ronald B Geskus, Le Van Tan, Nguyen Thuy Thuong Thuong, Guy E Thwaites
Journal: The Lancet Infectious Diseases (2020)

BackgroundXpert MTB/RIF Ultra (Xpert Ultra) might have higher sensitivity than its predecessor, Xpert MTB/RIF (Xpert), but its role in tuberculous meningitis diagnosis is uncertain. We aimed to compare Xpert Ultra with Xpert for the diagnosis of tuberculous meningitis in HIV-uninfected and HIV-infected adults.MethodsIn this prospective, randomised, diagnostic accuracy study, adults (≥16 years) with suspected tuberculous meningitis from a single centre in Vietnam were randomly assigned to cerebrospinal fluid testing by either Xpert Ultra or Xpert at baseline and, if treated for tuberculous meningitis, after 3–4 weeks of treatment. Test performance (sensitivity, specificity, and positive and negative predictive values) was calculated for Xpert Ultra and Xpert and compared against clinical and mycobacterial culture reference standards. Analyses were done for all patients and by HIV status.FindingsBetween Oct 16, 2017, and Feb 10, 2019, 205 patients were randomly assigned to Xpert Ultra (n=103) or Xpert (n=102). The sensitivities of Xpert Ultra and Xpert for tuberculous meningitis diagnosis against a reference standard of definite, probable, and possible tuberculous meningitis were 47·2% (95% CI 34·4–60·3; 25 of 53 patients) for Xpert Ultra and 39·6% (27·6–53·1; 21 of 53) for Xpert (p=0·56); specificities were 100·0% (95% CI 92·0–100·0; 44 of 44) and 100·0% (92·6–100·0; 48 of 48), respectively. In HIV-negative patients, the sensitivity of Xpert Ultra was 38·9% (24·8–55·1; 14 of 36) versus 22·9% (12·1–39·0; eight of 35) by Xpert (p=0·23). In HIV co-infected patients, the sensitivities were 64·3% (38·8–83·7; nine of 14) for Xpert Ultra and 76·9% (49·7–91·8; ten of 13) for Xpert (p=0·77). Negative predictive values were 61·1% (49·6–71·5) for Xpert Ultra and 60·0% (49·0–70·0) for Xpert. Against a reference standard of mycobacterial culture, sensitivities were 90·9% (72·2–97·5; 20 of 22 patients) for Xpert Ultra and 81·8% (61·5–92·7; 18 of 22) for Xpert (p=0·66); specificities were 93·9% (85·4–97·6; 62 of 66) and 96·9% (89·5–91·2; 63 of 65), respectively. Six (22%) of 27 patients had a positive test by Xpert Ultra after 4 weeks of treatment versus two (9%) of 22 patients by Xpert.InterpretationXpert Ultra was not statistically superior to Xpert for the diagnosis of tuberculous meningitis in HIV-uninfected and HIV-infected adults. A negative Xpert Ultra or Xpert test does not rule out tuberculous meningitis. New diagnostic strategies are urgently required.FundingWellcome Trust and the Foundation for Innovative New Diagnostics.
Clinical Behavior and Prognosis of Different Immunohistochemistry-Detected Subtypes of Invasive Breast Cancer: A Monoinstitutional Series
Authors: A. Ferro, C. Eccher, R. Triolo, A. Caldara, M.C. Di Pasquale, S. Moroso, L. Russo, M. Barbareschi, E. Galligioni
Journal: Annals of Oncology (2012)